Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

计划入组 216 人 · 首次发布于 2025 年 7 月 11 日

Team Science (The Liver Health Study)

计划入组 14 人 · 首次发布于 2025 年 4 月 11 日

CM for Patients With ALD After Liver Transplant

计划入组 30 人 · 首次发布于 2024 年 3 月 12 日

liver disease program

NTR-101

undisclosed drug (fibrotic liver disease/NASH), Engitix/Takeda

ALCOHOL RESEARCH UK

United Kingdom

Associated Capital

United States

LIVER INSTITUTE PLLC

United States

Rising Liver Cancer Cases in the US Linked to Alcohol-Associated Liver Disease and MASLD

Alcohol-Associated Liver Disease Market Poised for 31.1% CAGR Growth as First Disease-Modifying Therapies Near Approval

Larsucosterol Shows Promising 90-Day Mortality Reduction in Phase 2b Alcohol-Associated Hepatitis Trial